Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the 2019 Wedbush PacGrow Healthcare Conference being held August 13-14, 2019 in New York.

Details of the presentation are below:

Event: Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 13, 2019
Location: The Parker New York Hotel
Time: 9:45 – 10:15 AM ET

Additionally, Dr. Perros will hold 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their Wedbush representatives.

About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.

Entasis Company ContactKyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com

Investor Relations Contacts Tram Bui / Janhavi Mohite The Ruth Group (646) 536-7035 / 7026 tbui@theruthgroup.com jmohite@theruthgroup.com

Media ContactKirsten ThomasThe Ruth Group(508) 280-6592kthomas@theruthgroup.com

Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Entasis Therapeutics Charts.
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Entasis Therapeutics Charts.